SCHEMBL7005267

SCHEMBL7005267

Nc1ccn([C@H]2C[C@H](O)[C@@H](COc3cccc([N+](=O)[O-])c3O)O2)c(=O)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
P2RY2 P41231 3/20 0.45
P2RY4 P51582 3/20 0.45
P2RY6 Q15077 2/20 0.45
ADRB1 P08588 1/20 0.41
DNMT1 P26358 1/20 0.41
LMNA P02545 3/20 0.39
PDE3A Q14432 3/20 0.39
CACNA1F O60840 2/20 0.39
ALB P02768 2/20 0.39
MAPT P10636 2/20 0.39
CACNA1D Q01668 2/20 0.39
CACNA1S Q13698 2/20 0.39
CACNA1C Q13936 2/20 0.39
THRB P10828 1/20 0.38
MTOR P42345 1/20 0.38
MDM2 Q00987 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
POLG P54098 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7013075 0.84 POLB (0.59) POLBP2RY2P2RY4P2RY6ADRB1
SCHEMBL888173 0.82 POLB (0.54) POLBP2RY2P2RY4P2RY6ADRB1
SCHEMBL888072 0.80 POLB (0.51) POLBP2RY2P2RY4P2RY6ADRB1
SCHEMBL7012047 0.78 POLB (0.55) POLBP2RY2P2RY4P2RY6ADRB1
SCHEMBL5666385 0.77 POLB (0.68) POLBP2RY2P2RY4P2RY6ADRB1
SCHEMBL3200090 0.77 POLB (0.68) POLBP2RY2P2RY4P2RY6ADRB1
SCHEMBL3424606 0.77 POLB (0.68) POLBP2RY2P2RY4P2RY6ADRB1
SCHEMBL15617962 0.77 POLB (0.68) POLBP2RY2P2RY4P2RY6ADRB1
SCHEMBL1939479 0.77 POLB (0.68) POLBP2RY2P2RY4P2RY6ADRB1
SCHEMBL1962182 0.76 POLB (0.64) POLBP2RY2P2RY4P2RY6ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030207824-A1 Pyrimidine derivatives for labeled binding partners MATTEUCCI MARK D (US) 2003-11-06 US disclosed
EP-0719272-B1 PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS ISIS PHARMACEUTICALS INC (US) 2003-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207824-A1 Pyrimidine derivatives for labeled binding partners HNRNPH3, NSUN2, HNRNPH1 POLB 80/4885P2RY2 2699/4885P2RY4 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.